NewsSep 8, 2026
If you're on a first-line aromatase inhibitor plus a CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer, there's a new option worth understanding. On September 4, 2026, the FDA approved camizestrant (Etcamah) as the first cancer therapy triggered by a blood test rather than a growing tumor on a scan. In the trial that won it approval, switching the moment an ESR1 mutation appeared in the blood roughly doubled the time before the cancer advanced. Whether it also extends life is what the next few years of follow-up will answer.
NewsSep 4, 2026
On September 3, 2026, the FDA approved Zanvastro (zilganersen), the first drug shown in a controlled trial to slow Alexander disease itself rather than manage its symptoms. In the pivotal 54-patient study, quarterly spinal injections kept treated patients walking measurably better than untreated ones at about a year. It isn't a cure, and the delivery is a lumbar puncture every 12 weeks for life. But for families who until now had only supportive care, the ceiling on this disease has moved for the first time in decades.
NewsSep 2, 2026
For an adult who can't live with a CPAP mask, the answer is starting to be yes. AD109, a once-nightly pill, is the first drug in decades of trying that credibly opens the sleeping airway. In Phase 3 trials it cut breathing interruptions by roughly 44 to 47 percent from baseline versus about 7 to 18 percent on placebo, and the FDA is set to decide on approval by February 28, 2027. It has real side effects, and no trial has yet shown it lowers heart attacks or strokes, so it's a partial fix aimed at people the mask has failed, not a replacement for a CPAP that's working.
NewsSep 1, 2026
An FDA marketing order isn't a stamp of safety. It's a bet that the strongest ZYN yet will do more good for adult smokers who switch than harm to new users it pulls in. That's why the agency cleared 11 ZYN Ultra pouches on August 21, 2026, and also why it refused to let them carry the lower-risk-than-cigarettes claim it gave 3 mg and 6 mg ZYN two months earlier. If you already smoke and can trade cigarettes fully for pouches, the deal favors you. If you don't use nicotine, Ultra is the wrong product to start on.
NewsAug 31, 2026
For severe gum disease, yes, for many people. Daily omega-3 with low-dose aspirin, added to a deep cleaning, hit the treatment goal in about the same share of patients as the standard antibiotic combo, and both roughly doubled the result of cleaning alone. Combining them added nothing. Aspirin's bleeding risk means this trade isn't for everyone, but it's a live option worth raising with your periodontist before you accept a two-week course of amoxicillin and metronidazole.
MedicationAug 30, 2026
Yes. On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It joins semaglutide, liraglutide, and dulaglutide as a heart-protection option in this group. What tipped the approval wasn't a lower heart-attack rate. It was fewer deaths.
Heart HealthAug 30, 2026
If you're 70 or older, a statin is worth considering when your chance of a first major cardiovascular event is high enough to make daily medication worth it. The new STAREE atorvastatin trial strengthens that case, but it doesn't turn age itself into a reason to start. It found fewer events in a broad endpoint that included cardiovascular death, nonfatal heart attack, stroke, and coronary revascularization. The reduction was driven mainly by fewer heart attacks and coronary procedures. It did not extend disability-free survival. So the useful question is personal: how much event risk are you trying to prevent?
MedicationAug 30, 2026
Yes, for most adults with polycythemia vera who depend on regular phlebotomies, a newly approved once-weekly shot can replace them. The FDA cleared Mimrylo (rusfertide) on August 28, 2026. It's an add-on to standard care, not a cure, and hasn't yet been shown to prevent clots or extend life.
NewsAug 29, 2026
If your dermatomyositis keeps flaring through steroids and other immunosuppressants, there's finally a pill for it. Lisraya, approved on August 27, 2026, is the first oral drug ever cleared for this disease, and a randomized trial shows it quiets skin, restores function, and lets people cut their steroid dose at the same time. The label is narrow, the boxed warning is serious, and the list price runs about $35,000 a month. So it's not for milder or already well-controlled disease. For the patient whose disease keeps winning, though, this is a live new choice.
NewsAug 28, 2026
If you're stuck on three or more HIV pills a day because prior resistance closed off the existing single-tablet options, Bixlenvo is the first evidence-backed chance to collapse your regimen into one small daily tablet without losing viral suppression. If you're already undetectable on Biktarvy, the trial data don't show any advantage to switching.
NewsAug 27, 2026
Yes. In two large trials published in August 2026, about half of adults with at least half the scalp bare regrew hair to near-normal coverage after 24 weeks, and a meaningful minority regrew it all. That's the strongest response any oral JAK inhibitor has posted in severe alopecia areata. The catch: the hair holds only while you keep taking the pill, and Rinvoq still carries the JAK class boxed warning for infections, clots, and cancer.
NewsAug 27, 2026
If you have a bottle of Clear Eyes Maximum Itchy Eye Relief 15 mL with Lot 2552A and a September 30, 2027 expiration date, stop using it. That's the only bottle in the recall. Other Clear Eyes products and other lots aren't affected. Return yours to the retailer for a refund, and know the handful of symptoms that would send you to an eye doctor the same day.
CancerAug 26, 2026
Yes. In the trial that led to its August 26, 2026 approval, daraxonrasib (Rasonque) roughly doubled median survival over standard chemotherapy in adults with previously treated metastatic pancreatic cancer. It's a once-daily pill that blocks mutant RAS, the mutation driving nearly every pancreatic tumor, so most patients qualify without special testing. It's easier to stay on than chemo. Resistance still comes. And the drug is expensive.
CancerAug 22, 2026
If your high-risk melanoma has been fully removed, a personalized mRNA vaccine may help keep it from coming back. In a phase 2b trial, adding intismeran autogene (formerly mRNA-4157 or V940) to pembrolizumab led to fewer recurrences and fewer distant metastases than pembrolizumab alone. On August 19, 2026, Moderna and Merck said the larger phase 3 trial met its recurrence and distant-metastasis endpoints. But the vaccine isn't approved, and its topline release gave no effect sizes or survival data. The proven move today is still standard adjuvant care after surgery.
MedicationAug 17, 2026
If your PCOS is tied to higher weight or insulin resistance, a GLP-1 medicine like semaglutide may help the metabolic driver behind some of your symptoms, and better periods or lower testosterone may follow. But Ozempic is not a PCOS drug, and it is not a proven fertility treatment. The reliable part is weight loss and metabolic improvement; the reproductive claims come from small, short trials. If pregnancy is possible, timing matters: the PCOS guideline calls for effective contraception during GLP-1 use, and the Ozempic label advises stopping at least two months before a planned pregnancy.
Women's HealthAug 16, 2026
Hormone therapy hasn't been shown to prevent Alzheimer's. It earns its place for menopausal symptoms and bone protection, and the newer estrogen-and-brain studies matter on their own terms: some women using hormones show lower tau markers and larger brain regions tied to Alzheimer's risk. But no trial that tracks actual diagnoses has found fewer cases, and starting combined hormones at 65 or older raised dementia risk in the largest randomized dementia trial. Timing and formulation matter more than a simple yes or no.
LongevityAug 5, 2026
BPC-157 has an encouraging but incomplete human signal: a 53-person ulcerative-colitis enema trial reported a larger drop in disease-activity scores, but the full study appears only as a meeting abstract and FDA reviewers judged the data inadequate to prove efficacy or safety. For the uses most people actually want it for, healing an injury, a bad tendon, arthritic knees, faster recovery, the human evidence is not there yet. The musculoskeletal record is a 12-person BPC-only knee-pain subgroup in an uncontrolled chart review, plus animal and lab studies. It is biologically interesting enough to keep studying, and not proven enough to buy and inject on your own.
MedicationAug 2, 2026
Yes, part of what you drop on a GLP-1 is lean tissue, including some muscle, not only fat. But the trials show most of the loss is fat, and lean tissue makes up roughly a fifth to two fifths of the weight lost, a range that overlaps with dieting and bariatric surgery. The drug isn't melting muscle. The issue to watch is whether your strength holds, and that is something you can work on while the drug drives mostly fat loss.
Skin HealthAug 2, 2026
The best-proven way to prevent wrinkles is also the least glamorous: daily broad-spectrum sunscreen. In a randomized trial, steady daily use showed no detectable increase in skin aging after 4.5 years. Once fine lines start, topical retinoids have the strongest treatment evidence, and prescription tretinoin is the benchmark. Botulinum toxin, fillers, and resurfacing can each soften a specific kind of existing line, but they are not broad prevention tools. The plan that holds up is layered, not one product.
Digestive HealthAug 2, 2026
Something new is within reach for celiac disease: an add-on drug that could make accidental gluten less damaging to your gut. One pill, ZED1227, has already shown in people that it blunts the intestinal injury gluten causes during a controlled gluten challenge. That is meaningful progress. It is also not a cure, and not a license to eat bread. The gluten-free diet is still the only proven treatment, and the useful move now is to know which therapies have human proof behind them and which are still earlier signals.
